Scotch Corner IPO: What You Should Know Key Project Information Overview

X-twitter Linkedin Facebook-f Vimeo

GSK plc

  • Ticker: LON: GSK
GSK

GSK plc, formerly GlaxoSmithKline plc, is a British multinational pharmaceutical company headquartered in London, England.

About GSK plc

Latest GSK plc Share price

LON: GSK Dividends

Historical Data

Latest GSK plc News

GSK

Japan expands approval of GSK’s Arexvy to at-risk adults aged 18–49

GSK says Japan has expanded Arexvy eligibility to adults aged 18–49 at increased risk of RSV disease, including immunocompromised patients....
GSK plc

GSK partners with SBP Group to support bepirovirsen launch in China

GSK has entered an exclusive collaboration with SBP Group’s CTTQ unit to accelerate the launch of bepirovirsen, a potential first-in-class...
GSK

GSK wins China approval for Blenrep in previously treated multiple myeloma

The approval covers Blenrep plus bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma and is supported by...
GSK Plc

GSK adds pulmonary hypertension candidate HS235 through 35Pharma acquisition

GSK has closed its acquisition of 35Pharma, gaining HS235, a potential treatment for pulmonary hypertension that targets the activin receptor...
GSK

GSK expands Exdensur approval in China to CRSwNP

The NMPA has approved Exdensur for adults with chronic rhinosinusitis with nasal polyps, based on phase III data showing improved...
GSK

GSK wins China approval for Exdensur in severe asthma

GSK said China’s National Medical Products Administration approved Exdensur (depemokimab) for severe eosinophilic asthma in adults and adolescents aged 12...
GSK

GSK advances bepirovirsen in Europe with EMA review acceptance

The EMA has accepted GSK’s application for bepirovirsen in chronic hepatitis B, following Phase III data showing statistically significant functional...
GSK

GSK’s Ris-Rez granted Orphan Drug Status in Japan for small-cell lung cancer

GSK announced that its investigational antibody-drug conjugate, risvutatug rezetecan (Ris-Rez), has received orphan drug designation in Japan for treating small-cell...
GSK

GSK signs global licensing deal with Alfasigma for Linerixibat

GSK has entered a licensing agreement granting Alfasigma worldwide rights to develop and commercialise linerixibat, a late-stage treatment candidate for...
GSK

GSK secures EU approval for Exdensur in severe asthma and CRSwNP

GSK announced European Commission approval of Exdensur (depemokimab) as an add-on treatment for severe asthma with type 2 inflammation in...
GSK

GSK receives EU approval for Nucala in Eosinophilic COPD

GSK plc announced that the European Commission has approved Nucala (mepolizumab) as an add-on maintenance treatment for adults with uncontrolled...
GSK

GSK reports strong 2025 results and reaffirms long-term growth outlook

GSK delivered a strong financial performance in 2025, with sales of £32.7 billion driven by double-digit growth in Specialty Medicines...
More News

Share this page

Twitter
LinkedIn
Facebook
Email
WhatsApp

Data policy – All information should be used for indicative purposes only. You should independently check data before making any investment decision and or seek professional advice. DirectorsTalk cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used.

Follow us on Social Media:

Home X-twitter Linkedin Facebook Spotify Apple